PDEI‐5 for Erectile Dysfunction: A Potential Role in Seizure Susceptibility

ABSTRACTIntroductionThere is a high prevalence of erectile dysfunction (ED) in men with epilepsy; however, few studies have been conducted concerning the treatment of ED in this neurological group.AimThe main purpose of this review is to highlight the influence of phosphodiesterase type 5 inhibitor (PDEI‐5) for ED on seizure susceptibility.MethodsAll available online articles with information pertaining to PDEI‐5 and seizure susceptibility were included in this review.Main Outcome MeasuresThe main outcome assessed demonstrated the intriguing role of PDEI‐5 and its metabolites on seizure susceptibility.ResultsCase reports in men without epilepsy described seizure occurrence and electrophysiological changes following sildenafil, tadalafil, or vardenafil treatment. Consistent with these findings, preclinical studies suggested a proconvulsant effect of PDEI‐5 on models of seizure induction.ConclusionsEvidence suggests an influence of PDEI‐5 on seizure susceptibility in humans. In addition, preclinical studies have demonstrated the role of nitric oxide metabolites in the facilitation of paroxysmal phenomenon. Although there are many causes of seizures, medical professionals should be aware of the possible influence of PDEI‐5 on seizure susceptibility. Further investigation by physicians and scientists is required to improve our understanding of this important topic. Matos G, Scorza FA, Cavalheiro EA, Tufik S, and Andersen ML. PDEI‐5 for erectile dysfunction: A potential role in seizure susceptibility. J Sex Med 2012;9:2111–2121.